Last reviewed 2026-05-31 · How we verify

Sunrabin (ENOCITABINE)

Phase 2 active Small molecule ✓ Verified May 2026

Sunrabin (generic name: ENOCITABINE) is a Nucleoside Metabolic Inhibitor drug. It is currently in Phase 2 development.

Sunrabin works by incorporating itself into viral DNA, thereby disrupting its replication and transcription.

Sunrabin is a small molecule with synonyms including ENOCITABINA, ENOCITABINE, NSC-239336, and SUNRABIN.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ENOCITABINE
Drug class	Nucleoside Metabolic Inhibitor
Modality	Small molecule
Therapeutic area	Metabolic
Phase	Phase 2

Mechanism of action

Imagine Sunrabin as a puzzle piece that fits into the viral DNA's replication machinery. By doing so, it prevents the virus from making copies of itself, which can help slow down the progression of the infection. This mechanism is specific to viral replication and is distinct from how our own cells replicate DNA.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Sunrabin CI brief — competitive landscape report
Sunrabin updates RSS · CI watch RSS

Frequently asked questions about Sunrabin

What is Sunrabin?

Sunrabin (ENOCITABINE) is a Nucleoside Metabolic Inhibitor drug.

How does Sunrabin work?

Sunrabin works by incorporating itself into viral DNA, thereby disrupting its replication and transcription.

What is the generic name of Sunrabin?

ENOCITABINE is the generic (nonproprietary) name of Sunrabin.

What drug class is Sunrabin in?

Sunrabin belongs to the Nucleoside Metabolic Inhibitor class. See all Nucleoside Metabolic Inhibitor drugs at /class/nucleoside-metabolic-inhibitor.

What development phase is Sunrabin in?

Sunrabin is in Phase 2.

Drug class: All Nucleoside Metabolic Inhibitor drugs
Therapeutic area: All drugs in Metabolic

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing